Additionally, a nomogram model integrating S100A9 and MYH2 further improved diagnostic performance, achieving an AUC of 0.889, providing a theoretical foundation for risk assessment and screening of COPD-related NAFLD. Here, S100A9 is linked to metabolic dysfunction-associated steatotic liver disease.